EPHA2 and neoplasm: Analogously, Cui and colleagues demonstrated that CRISPR/Cas9-mediated deletion of the EphA2-SE effectively downregulates its target gene, EphA2, which in turn significantly suppresses cell proliferation and metastasis by inhibiting the PI3K/AKT and Wnt/β-catenin signaling pathways in multiple tumor cells [86].